Get all premium features to the best stock analysis tool

TEM expands 2026 reach via strategic collaborations, boosting oncology, diagnostics and AI-driven insights to enhance care and drug development.

Tempus (TEM) reported earnings 30 days ago. What's next for the stock?

Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth and pricing leverage.

Recursion is using AI to develop new drug candidates much more efficiently than the overall industry. Tempus AI's $1.27 billion trailing revenue comes from a clinical data flywheel that no competitor can build from scratch.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global nonprofit focused on blood cancer patient support, research, and advocacy, today announced a strategic collaboration to develop a comprehensive, patient-centered, real-world registry for pediatric acute myeloid leukemia (pAML), a rare and aggressive blood cancer. Part of.

TEM expands its clinical software push with TIME trial-matching, Tempus Next care intelligence and an upgraded Tempus One AI assistant for providers.

TEM advances precision oncology as studies validate IPS, PurIST and xF+ diagnostics, highlighting stronger guidance for cancer therapy and biomarker detection.